As part of Lilly’s ‘In China, For China’ strategy, the small molecule drug is intended to help the 276 million Chinese patients affected by high cholesterol.
Innovent and Lilly form a broad alliance to develop at least three cancer drugs over the next decade.
Eli Lilly and Company will invest US$350 million to expand its insulin cartridge manufacturing capacity in China.
Hutchison MediPharma has entered into a collaboration with Eli Lilly to develop fruquintinib, a targeted oncology therapy against solid tumors.
Two phase III clinical studies show that linagliptin improved blood glucose control in Asian adults with type II diabetes.
Elanco has announced a US$100 million investment to purchase a minority equity stake in China Animal Healthcare Ltd.
Eli Lilly and Company announced this month an expanded collaboration with Novast Laboratories to build a portfolio of Lilly branded generic medicines in China.